Products
Ciprofibrate was commercially available in many countries in capsule form (Hyperlipen, off label). It was approved in 1993 and has not been available since 2013.
Structure and properties
Ciprofibrate (C13H14Cl2O3, Mr = 289.2 g/mol) is a racemate and a phenoxyisobutyric acid derivative. It exists as a white to pale yellow powder that is practically insoluble in water.
Effects
Ciprofibrate (ATC C10AB08) is lipid-lowering. It reduces cholesterol levels and triglycerides and increases HDL. The effects are due to activation of nuclear receptors of the PPAR (peroxisome proliferator-activated receptor) family, which regulate genes that play important roles in lipid and glucose metabolism.
Indications
- For the treatment of severe hypertriglyceridemia.
- For the treatment of mixed hyperlipidemia as a 2nd-line agent.
Dosage
According to the professional information. The capsules are taken once a day, regardless of meals.
Contraindications
Ciprofibrate is contraindicated in hypersensitivity, severe hepatic insufficiency, severe renal insufficiency, during pregnancy and lactation. It should not be combined with other fibrates. For complete precautions, see the drug label.
Interactions
Combination with other fibrates or statins is not advised. Other drug interactions are possible with vitamin K antagonists, agents with high protein binding, and estrogens.
Adverse effects
Possible adverse effects include skin reactions, muscle pain, muscle disorders (very rarely rhabdomyolysis), headache, dizziness, digestive disturbances, abnormal liver enzymes, and fatigue.
